Literature DB >> 21654961

Graves' Disease following Interferon Therapy for Chronic Hepatitis C Infection.

Omayma El Shafie1, Samir Hussein, Waheed El Awady, Nicholas Woodhouse.   

Abstract

We describe the first case of Graves' disease occurring at Sultan Qaboos University Hospital, Oman, in a patient who was under treatment with interferon alfa for HCV infection. INF-α is now being widely used to treat patients with a variety of disorders including infection with hepatitis C virus. Clinical thyroid disease, hypo and hyperthyroidism can occur in up to 15% of patients. We emphasize the need for thyroid function screening before and during therapy to identify patients early in the course of their disease..

Entities:  

Keywords:  Antibodies, thyroid; Case Report, Oman; Interferon; Thyroid function test; Thyrotoxicosis

Year:  2008        PMID： 21654961      PMCID： PMC3087743     

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN： 2075-051X


  7 in total

1.  Life-threatening thyrotoxicosis induced by combination therapy with PEG-interferon and ribavirin in chronic hepatitis C.

Authors:  Yong Q Lin; Xiangbing Wang; Meena S Murthy; Sumon Agarwala
Journal:  Endocr Pract       Date:  2005 Mar-Apr       Impact factor: 3.443

2.  Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease.

Authors:  Nathalie Lévy Bohbot; Jacques Young; Jacques Orgiazzi; Catherine Buffet; Maud François; Brigitte Bernard-Chabert; Céline Lukas-Croisier; Brigitte Delemer
Journal:  Eur J Endocrinol       Date:  2006-03       Impact factor: 6.664

3.  Association between human leukocyte antigen (HLA) and interferon- induced thyroid diseases in four patients with HCV-related chronic hepatitis.

Authors:  Giancarlo Labbadia; Antonio Martocchia; Antonio Mammarella; Vincenzo Paoletti; Antonio Rocco; Rosalba Benvenuto; Proietti Antonella; D'Urso Rosaria; Simonetta Trabace; Antonino Musca; Paolo Falaschi
Journal:  Neuro Endocrinol Lett       Date:  2005-04       Impact factor: 0.765

4.  Graves' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C.

Authors:  S Koizumi; Y Mashio; H Mizuo; A Matsuda; K Matsuya; H Mizumoto; A Ikota; M Beniko; Y Iriuda
Journal:  Intern Med       Date:  1995-01       Impact factor: 1.271

5.  Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis.

Authors:  Vincent Wong; Angela Xi-Li Fu; Jacob George; N Wah Cheung
Journal:  Clin Endocrinol (Oxf)       Date:  2002-06       Impact factor: 3.478

Review 6.  The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification.

Authors:  Jamie C Mandac; Sonal Chaudhry; Kenneth E Sherman; Yaron Tomer
Journal:  Hepatology       Date:  2006-04       Impact factor: 17.425

7.  The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-alpha2beta and Ribavirin.

Authors:  Huy A Tran; Tracey L Jones; Robert G Batey
Journal:  BMC Endocr Disord       Date:  2005-10-12       Impact factor: 2.763
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.